Revolution Medicines, Inc.

NASDAQ:RVMD

46.18 (USD) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q3
Revenue 000.74203.8247.01415.333.3569.1167.5789.461.1018.69810.1318.75112.66110.02511.54612.08812.50612.28113.16610.347
Cost of Revenue 2.7972.7632.8582.1451.7732.5332.5992.4332.3342.292.06246.47345.93640.85837.00634.87132.91827.45727.4922.96220.11721.18618.181
Gross Profit -2.797-2.763-2.116-2.1452.0514.48112.7310.9236.7825.2887.398-45.372-37.238-30.727-28.255-22.21-22.893-15.911-15.402-10.456-7.836-8.02-7.834
Gross Profit Ratio 00-2.85200.5360.6390.830.2750.7440.6980.782-41.21-4.281-3.033-3.229-1.754-2.284-1.378-1.274-0.836-0.638-0.609-0.757
Reseach & Development Expenses 133.023118.021146.867107.73597.98168.94766.12769.45561.00156.4953.68146.47345.93640.85837.00634.87132.91827.45727.4922.96220.11721.18618.181
General & Administrative Expenses 21.71122.83832.24415.51314.6413.22410.9110.43410.2049.0378.6927.7917.2976.675.8255.3415.0915.1714.1623.1032.7252.4163.835
Selling & Marketing Expenses -0.8880-1.24400000000000000000000
SG&A 20.82322.8383115.51314.6413.22410.9110.43410.2049.0378.6927.7917.2976.675.8255.3415.0915.1714.1623.1032.7252.4163.835
Other Expenses 0.016-2.809000000000000000000000
Operating Expenses 153.846140.859177.867123.248112.62182.17177.03779.88971.20565.52762.37354.26453.23347.52842.83140.21238.00932.62831.65226.06522.84223.60222.016
Operating Income -156.643-140.859-179.983-123.248-108.797-75.157-61.707-76.533-62.089-57.949-52.913-53.163-44.535-37.397-34.08-27.551-27.984-21.082-19.564-13.559-10.561-10.436-11.669
Operating Income Ratio 00-242.5650-28.451-10.715-4.025-22.805-6.811-7.647-5.593-48.286-5.12-3.691-3.894-2.176-2.791-1.826-1.618-1.084-0.86-0.793-1.128
Total Other Income Expenses Net 23.4124.85618.78910.94710.4997.0595.0772.9070.8670.3020.2370.2230.2360.2210.2380.330.7110.8880.5950.7410.4420.3050.33
Income Before Tax -133.233-116.003-161.194-112.301-98.298-68.098-56.63-73.626-61.222-57.647-52.676-52.94-44.299-37.176-33.842-27.221-27.273-20.194-18.969-12.818-10.119-10.131-11.339
Income Before Tax Ratio 00-217.2430-25.706-9.709-3.694-21.939-6.716-7.607-5.568-48.084-5.093-3.67-3.867-2.15-2.72-1.749-1.569-1.025-0.824-0.769-1.096
Income Tax Expense 0-2.7630.3433.867-1.773-9.592-0.123-0.297-0.867-0.302-1.8250.2230.2360.2330.3620.347-0.058-0.675-4.3730.7660.470.3350.363
Net Income -133.233-116.003-161.537-108.434-98.298-58.506-56.507-73.329-60.355-57.345-52.676-52.94-44.299-37.176-34.204-27.221-27.215-19.519-14.596-12.818-10.119-10.131-11.339
Net Income Ratio 00-217.7050-25.706-8.341-3.686-21.85-6.621-7.567-5.568-48.084-5.093-3.67-3.909-2.15-2.715-1.691-1.207-1.025-0.824-0.769-1.096
EPS -0.81-0.7-1.14-0.99-0.92-0.62-0.63-0.87-0.81-0.77-0.71-0.72-0.6-0.53-0.52-0.42-0.46-0.67-0.4-0.35-0.28-0.28-0.31
EPS Diluted -0.81-0.7-1.14-0.99-0.92-0.62-0.63-0.87-0.81-0.77-0.71-0.72-0.6-0.53-0.52-0.42-0.46-0.67-0.4-0.35-0.28-0.28-0.31
EBITDA -153.846-140.859-177.125-123.248-108.797-75.157-56.63-71.193-58.888-55.357-52.676-51.189-42.458-35.486-33.828-25.574-25.583-18.629-18.081-11.92-9.28-9.308-10.615
EBITDA Ratio 00-238.7130-28.451-10.715-3.694-21.214-6.46-7.305-5.568-46.493-4.881-3.503-3.866-2.02-2.552-1.613-1.496-0.953-0.756-0.707-1.026